Rimidi Patents – Insights & Stats (Updated 2023)

Rimidi has a total of 15 patents globally, out of which 5 have been granted. Of these 15 patents, more than 33% patents are active. The United States of America is where Rimidi has filed the maximum number of patents, followed by Canada. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Rimidi.

Rimidi was founded in 2012. Rimidi is a software tool that enables patients and physicians to detect gaps in diabetes treatment and the measures required to fix those gaps, reach patient targets, and create a more efficient cycle of care.

Do read about some of the most popular patents of Rimidi which have been covered by us in this article and also you can find Rimidi patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Rimidi patent portfolio.

How many patents do the Founder and CEO of Rimidi have?

The Founder and CEO Lucienne Marie Ide have 12 patents.

How many patents does Rimidi have?

Rimidi has a total of 15 patents globally. These patents belong to 5 unique patent families. Out of 15 patents, 5 patents are active.

How Many Patents did Rimidi File Every Year?

Rimidi Patent Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantRimidi Applications FiledRimidi Patents Granted
20161
20151
201463
20136
20123

How many Rimidi patents are Alive/Dead?

Worldwide Patents

Rimidi Patent Portfolio

How Many Patents did Rimidi File in Different Countries?

Rimidi Worldwide Patent Filing

Countries in which Rimidi Filed Patents

CompanyPatent
United States Of America9
Canada3

Where are Research Centers of Rimidi Patents Located?

The Research Centers of Rimidi Patents is the United States of America.

Best Rimidi Patents

US8768673B2, US8756043B2, US8744828B2 are the most popular patent in the Rimidi portfolio. They have received 9 citations so far from companies.

Below is the list of most cited patents of Rimidi:

Publication NumberCitation Count
US8768673B29
US8756043B29
US8744828B29
US20140297246A17
US20150347707A16
US20140316759A16
US20150347708A13
US20140303995A13
WO2014018806A11

What Percentage of Rimidi US Patent Applications Were Granted?

Rimidi (Excluding its subsidiaries) has filed 6 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 3 have been granted leading to a grant rate of 50%.

Below are the key stats of Rimidi patent prosecution at the USPTO.

Which Law Firms Filed Most US Patents for Rimidi?

Law FirmTotal ApplicationsSuccess Rate
Eversheds Sutherland Us Llp3100%
Nesbitt Ip Llc30%

List of Rimidi patents

Rimidi PatentsTitle
US8768673B2Computer-Implemented System And Method For Improving Glucose Management Through Cloud-Based Modeling Of Circadian Profiles
US8756043B2Blood Glucose Meter And Computer-Implemented Method For Improving Glucose Management Through Modeling Of Circadian Profiles
US8744828B2Computer-Implemented System And Method For Improving Glucose Management Through Modeling Of Circadian Profiles
CA2880202CImproved Glucose Management Through Modeling Of Circadian Profiles
CA2880168CBlood Glucose Meter For Improving Glucose Management Through Modeling Of Circadian Profiles
US20150379229A1Computer-Implemented System And Method For Improving Glucose Management Through Modeling Of Circadian Profiles
US20150347707A1Computer-Implemented System And Method For Improving Glucose Management Through Cloud-Based Modeling Of Circadian Profiles
US20150347708A1Blood Glucose Meter And Computer-Implemented Method For Improving Glucose Management Through Modeling Of Circadian Profiles
US20140316759A1Computer-Implemented System And Method For Facilitating Accurate Glycemic Control By Modeling Blood Glucose Using Cloud-Based Circadian Profiles
US20140303995A1Computer-Implemented System And Method For Facilitating Accurate Glycemic Control By Modeling Blood Glucose Using Circadian Profiles
US20140297246A1Blood Glucose Meter And Computer-Implemented Method For Facilitating Accurate Glycemic Control By Modeling Blood Glucose Using Circadian Profiles
WO2014018797A1Improved Glucose Management Through Cloud-Based Modeling Of Circadian Profiles
WO2014018806A1Blood Glucose Meter For Improving Glucose Management Through Modeling Of Circadian Profiles
WO2014018788A1Improved Glucose Management Through Modeling Of Circadian Profiles
CA2880204A1Improved Glucose Management Through Cloud-Based Modeling Of Circadian Profiles

What are Rimidi key innovation segments?

What Technologies are Covered by Rimidi?

The chart below distributes patents filed by Rimidi in different countries on the basis of the technology protected in patents. It also represents the markets where Rimidi thinks it’s important to protect particular technology inventions.

R&D Focus: How has Rimidi search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Rimidi?

Related Articles

VoxelSensors Patents – Insights & Stats (Updated 2024)

VoxelSensors has a total of 36 patents globally, out of which 8 have been granted. Of these 36 patents, more than 94% patents are active. Europe (EPO) is where VoxelSensors has filed the maximum number of patents, followed by China and Israel. Parallelly, Belgium seems to be the main focused

Read More »

Alphapharm Patents – Insights & Stats (Updated 2024)

Alphapharm has a total of 108 patents globally, out of which 43 have been granted. Of these 108 patents, more than 18% patents are active. Australia is where Alphapharm has filed the maximum number of patents, followed by Europe (EPO) and United States of America. Parallelly, Australia seems to be

Read More »

Leave a Comment

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.